Skip to main content
main-content
Top

01-04-2018 | Medication adherence | Article

A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study

Journal: Diabetes Therapy

Authors: Andrew McGovern, William Hinton, Silvio Calderara, Neil Munro, Martin Whyte, Simon de Lusignan

Publisher: Springer Healthcare

share
SHARE

Abstract

Introduction

Longer medication persistence in type 2 diabetes (T2D) is associated with improved glycaemic control. It is not clear which oral therapies have the best persistence. The objective of this study was to compare medication persistence across different oral therapies in people with T2D.

Methods

We performed a retrospective cohort analysis using a primary-care-based population, the Royal College of General Practitioners Research and Surveillance Centre cohort. We identified new prescriptions for oral diabetes medication in people with type 2 diabetes between January 1, 2004 and July 31, 2015. We compared median persistence across each class. We also compared non-persistence (defined as a prescription gap of ≥ 90 days) between classes, adjusting for confounders, using Cox regression. Confounders included: age, gender, ethnicity, socioeconomic status, alcohol use, smoking status, glycaemic control, diabetes duration, diabetes complications, comorbidities, and number of previous and concurrent diabetes medications.

Results

We identified 60,327 adults with T2D. The majority 42,810 (70.9%) of those had one or more oral medications prescribed; we measured persistence in those patients (who were prescribed 55,728 oral medications in total). Metformin had the longest median persistence (3.04 years; 95% CI 2.94–3.12). The adjusted hazard ratios for non-persistence compared with metformin were: sulfonylureas HR 1.20 (1.16–1.24), DPP-4 inhibitors HR 1.43 (1.38–1.49), thiazolidinediones HR 1.71 (95% CI 1.64–1.77), SGLT2 inhibitors HR 1.04 (0.93–1.17), meglitinides HR 2.25 (1.97–2.58), and alpha-glucosidase inhibitors HR 2.45 (1.98–3.02). The analysis of SGLT2 inhibitors was limited by the short duration of follow-up for this new class. Other factors associated with reduced medication persistence were female gender, younger age, and non-white ethnicity.

Conclusions

Persistence is strongly influenced by medication class and should be considered when initiating treatments.
Literature
1.
World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003.
2.
Jermendy G, et al. Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus. Med Sci Monit. 2012;18(2):Cr72–7. CrossRefPubMedPubMedCentral
3.
Abegunde DO, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370(9603):1929–38. CrossRefPubMed
4.
Trogdon JG, et al. Peer reviewed: costs of chronic diseases at the state level: the chronic disease cost calculator. Prev Chron Dis. 2015;12:150131.
5.
Al-Majed HT, et al. Adherence of type-2 diabetic patients to treatment. Kuwait Med J. 2014;46(3):225–32.
6.
Awodele O, Osuolale JA. Medication adherence in type 2 diabetes patients: study of patients in Alimosho General Hospital, Igando, Lagos, Nigeria. Afr Health Sci. 2015;15(2):513–22. CrossRefPubMedPubMedCentral
7.
Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19(4):279–84. CrossRefPubMed
8.
Peyrot M, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–9. CrossRefPubMedPubMedCentral
9.
Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24. CrossRefPubMed
10.
Iglay K, et al. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin. 2015;31(7):1283–96. CrossRefPubMed
11.
Aikens JE, Piette JD. Longitudinal association between medication adherence and glycaemic control in type 2 diabetes. Diabet Med. 2013;30(3):338–44. CrossRefPubMedPubMedCentral
12.
Buysman EK, et al. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32(4):341–55. CrossRefPubMedPubMedCentral
13.
Kim N, Agostini JV, Justice AC. Refill adherence to oral hypoglycemic agents and glycemic control in veterans. Ann Pharmacother. 2010;44(5):800–8. CrossRefPubMedPubMedCentral
14.
Penning-van Beest FJ, et al. Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin. 2008;24(9):2523–9. CrossRefPubMed
15.
Rozenfeld Y, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71–5. PubMed
16.
Wu CH, et al. The eight-item Morisky Medication Adherence Scale (MMAS-8) score was associated with glycaemic control in diabetes patients. Hypertension. 2014;64(Suppl 1):A558.
17.
Heaton PC, Tundia NL, Luder HR. US emergency departments visits resulting from poor medication adherence: 2005–07. J Am Pharm Assoc. 2003;53(5):513–9. CrossRef
18.
Hong JS, Kang HC. Relationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South Korea. Med Care. 2011;49(4):378–84. CrossRefPubMed
19.
Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149–53. CrossRefPubMed
20.
Zhu VJ, et al. Oral hypoglycemic agent adherence and hospitalization among patients with type 2 diabetes: a call for enhanced guidelines. Pharmacoepidemiol Drug Saf. 2012;21(S3):29.
21.
Egede LE, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35(12):2533–9. CrossRefPubMedPubMedCentral
22.
Hansen RA, et al. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin Ther. 2010;32(7):1308–19. CrossRefPubMed
23.
Lee WC, et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19(7):31–41. PubMed
24.
Macewan JP, et al. Penny-wise, pound-foolish: association between medication adherence, out-of-pocket expenses, and health care costs in medicare patients with type 2 diabetes. Diabetes. 2015;64(S1):A69.
25.
Nasseh K, et al. Cost of medication nonadherence associated with diabetes, hypertension, and dyslipidemia. Am J Pharm Benefits. 2012;4(2):e41–7.
26.
Shenolikar RA, et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. Clin Ther. 2006;28(8):1199–207. CrossRefPubMed
27.
Stuart BC, et al. Increased persistency in medication use by US Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings. Diabetes Care. 2009;32(4):647–9. CrossRefPubMedPubMedCentral
28.
Hong S, et al. Compliance with anti-diabetic medication improves cardiovascular outcomes in patients with type 2 diabetes. Diabetes. 2013;62(S1):A372.
29.
Wu C-S. Antihyperglycemic adherence and risk of stroke among type II diabetes mellitus: a population-based retrospective cohort study. Dissertation. University of South Carolina: Columbia; 2012.
30.
Currie CJ, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279–84. CrossRefPubMedPubMedCentral
31.
Pladevall M, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800–5. CrossRefPubMedPubMedCentral
32.
Salas M, et al. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health. 2009;12(6):915–22. CrossRefPubMed
33.
Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015;32(6):725–37. CrossRefPubMed
34.
Cramer JA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7. CrossRefPubMed
35.
Peterson AM, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12. CrossRefPubMed
36.
Raebel MA, et al. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11–21. CrossRefPubMedPubMedCentral
37.
Correa A, et al. Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open. 2016;6(4):e011092. CrossRefPubMedPubMedCentral
38.
McGovern A, et al. Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. BMJ Open. 2016;6(11):e012801. CrossRefPubMedPubMedCentral
39.
de Lusignan S, et al. A method of identifying and correcting miscoding, misclassification and misdiagnosis in diabetes: a pilot and validation study of routinely collected data. Diabet Med. 2010;27(2):203–9. CrossRefPubMed
40.
de Lusignan S, et al. Miscoding, misclassification and misdiagnosis of diabetes in primary care. Diabet Med. 2012;29(2):181–9. CrossRefPubMed
41.
Office for National Statistics. Ethnicity. 2015. https://​www.​ons.​gov.​uk/​peoplepopulation​andcommunity/​culturalidentity​/​ethnicity. Accessed 28 Dec 2017.
42.
Del Prato S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17(6):581–90. CrossRefPubMed
43.
Matthews DR, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. 1998;15(4):297–303. CrossRefPubMed
44.
Fisher L, et al. Emotional distress is linked to medication adherence in type 2 diabetes. Diabetes. 2009;58:A478.
45.
Bezie Y, et al. Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes. Diabetes Metab. 2006;32(6):611–6. CrossRefPubMed
46.
Egede E, et al. Regional, geographic, and ethnic differences in medication adherence among adults with type 2 diabetes. Ann Pharmacother. 2011;45(2):169–79. CrossRefPubMed
47.
Shenolikar RA, et al. Race and medication adherence in medicaid enrollees with type-2 diabetes. J Natl Med Assoc. 2006;98(7):1071–7. PubMedPubMedCentral
48.
Oldroyd J, et al. Diabetes and ethnic minorities. Postgrad Med J. 2005;81(958):486–90. CrossRefPubMedPubMedCentral
49.
Gonzalez JS, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31(12):2398–404. CrossRefPubMedPubMedCentral
50.
Leblond J, et al. Predictors of nonpersistence with thiazolidinediones in patients with type 2 diabetes. Can J Diabetes. 2005;29(2):95–102.
51.
Gwadry-Sridhar F, et al. Influence of previous medication compliance on future compliance in patients with type 2 diabetes. Diabetes. 2010;59:A346.
52.
Toyoda M, et al. Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res Clin Pract. 2014;106(3):451. CrossRefPubMed
53.
Feldman BS, et al. Defining the role of medication adherence in poor glycemic control among a general adult population with diabetes. PLoS One. 2014;9(9):e108145. CrossRefPubMedPubMedCentral
54.
Hawa MI, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. 2013;36(4):908–13. CrossRefPubMedPubMedCentral
55.
McGovern A, et al. A comparison of adherence and persistence by medication class in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2017. https://​doi.​org/​10.​1111/​dom.​13160.
56.
Gwadry-Sridhar F, et al. Understanding predictors of compliance in fixed-dose combination vs loose-dose combination therapy for treatment of type 2 diabetes. Diabetes. 2010;59:A346.
57.
Chen CC, Tseng CH, Cheng SH. Continuity of care, medication adherence, and health care outcomes among patients with newly diagnosed type 2 diabetes: a longitudinal analysis. Med Care. 2013;51(3):231–7. CrossRefPubMed
58.
Hessler DM, et al. Low patient trust in their primary care provider predicts medication nonadherence 12 months later. Diabetes. 2014;63:A194.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions